Completed OBSERVATIONAL NCT05243823

Vaginal Estradiol Tablets (Vagifem®) and Endometrial Cancer Risk in the Treatment of Postmenopausal Vaginal Atrophy

Vaginal Estradiol Tablets (Vagifem®) and Endometrial Cancer Risk in the Treatment of Postmenopausal Vaginal Atrophy: A Register-based Cohort Study in Postmenopausal Women

Sponsor: Novo Nordisk A/S

Conditions Postmenopausal Vaginal Atrophy

Interventions Non-Vagifem® LDVE, Estradiol Vagifem®

Updated 6 times since 2022 Last updated: Dec 22, 2022 Started: Jan 15, 2022 Primary completion: Jul 31, 2022 Completion: Jul 31, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Postmenopausal Vaginal Atrophy and is currently completed. Novo Nordisk A/S leads this study, which shows 6 recorded versions since 2022 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2023 — Jul 2024 [monthly]

Completed
Sep 2022 — Jan 2023 [monthly]

Completed

Status: Not Yet Recruiting → Completed
Jun 2022 — Sep 2022 [monthly]

Not Yet Recruiting

▶ Show 1 earlier version

Mar 2022 — Jun 2022 [monthly]

Not Yet Recruiting

First recorded

Jan 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novo Nordisk A/S

Data source: Novo Nordisk A/S

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Soeborg, Denmark